Rubraca Gets FDA Approval for Prostate Cancer!
PCEC is so happy to announce that the U.S. Food and Drug Administration (FDA) approved rucaparib, a new medication to treat patients with a BRCA mutation for advanced prostate cancer. Medical advancements like these are what continue to inspire and bring hope to everyone in the fight against prostate cancer! Click below to learn more.
If you are interested in learning more about the BRCA mutation and prostate cancer treatment check out BRCABlue.com!